CUE Cue Biopharma, Inc.: Net earnings per share for the last 12 months

Cue Biopharma (CUE) - corporate logo

Cue Biopharma, Inc. (CUE) is implementing green chemistry principles to ensure the safe disposal of chemicals and energy efficiency. The company relies on a staff of biochemists attracted by academic freedom and significant investment in research and development. The price indicator on the chart with the current value of -62.90 reflects the dynamics of a business creating unique molecules to combat tumors with support from Merck and strict FDA oversight.

Cue Biopharma (CUE) Net earnings per share for the last 12 months: for the period 02/11/2024 - 11/17/2026

CUE (Cue Biopharma Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
Fundamental valuation:CUE Cue Biopharma, Inc.
Finished products of Cue Biopharma

This indicator measures the rolling year net earnings per share dynamics, reflecting the actual efficiency of Cue Biopharma, Inc. (CUE) business capitalization relative to operating expenses. By analyzing this rolling year YoY EPS growth chart, an investor can see the impact of investments in the Immuno-STAT platform on margins, which is critical for biotech innovators with high R&D potential.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|PDS Biotechnology Corp (PDSB) - Earnings per share for the last twelve months|Sonnet BioTherapeutics Holdings, Inc. - Earnings per share for the trailing year|MAIA (MAIABiotech.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Liminatus Pharma Inc.|Earnings per share for the last twelve months lavatherapeutics.com (LVTX)|NXTC: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months